Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631

Kelly E. Faulk; John A. Kairalla; Zo Ann E. Dreyer; Andrew J. Carroll; Nyla A. Heerema; Meenakshi Devidas; William L. Carroll; Elizabeth A. Raetz; Mignon L. Loh; Stephen P. Hunger; Michael Borowitz; Cindy Wang; Erin Guest; Patrick A. Brown

doi:10.1002/pbc.30467

Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631

Kelly E. Faulk, John A. Kairalla, Zo Ann E. Dreyer, Andrew J. Carroll, Nyla A. Heerema, Meenakshi Devidas, William L. Carroll, Elizabeth A. Raetz, Mignon L. Loh, Stephen P. Hunger, Michael Borowitz, Cindy Wang, Erin Guest, Patrick A. Brown

Research output: Contribution to journal › Article › peer-review

Abstract

We measured minimal residual disease (MRD) by multiparameter flow cytometry at three time points (TP) in 117 infants with KMT2A (lysine [K]-specific methyltransferase 2A)-rearranged and 58 with KMT2A-germline acute lymphoblastic leukemia (ALL) on Children's Oncology Group AALL0631 study. For KMT2A-rearranged patients, 3-year event-free survival (EFS) by MRD-positive (≥0.01%) versus MRD-negative (<0.01%) was: TP1: 25% (±6%) versus 49% (±7%; p =.0009); TP2: 21% (±8%) versus 47% (±7%; p <.0001); and TP3: 22% (±14%) versus 51% (±6%; p =.0178). For KMT2A-germline patients, 3-year EFS was: TP1: 88% (±12%) versus 87% (±5%; p =.73); TP2: 100% versus 88% (±5%; p =.24); and TP3: 100% versus 87% (±5%; p =.53). MRD was a strong independent outcome predictor in KMT2A-rearranged, but not KMT2A-germline infant ALL.

Original language	English
Article number	e30467
Journal	Pediatric Blood and Cancer
Volume	70
Issue number	9
DOIs	https://doi.org/10.1002/pbc.30467
State	Published - Sep 2023
Externally published	Yes

Keywords

acute lymphoblastic leukemia
infant leukemia
minimal residual disease

Access to Document

10.1002/pbc.30467

Cite this

Faulk, K. E., Kairalla, J. A., Dreyer, Z. A. E., Carroll, A. J., Heerema, N. A., Devidas, M., Carroll, W. L., Raetz, E. A., Loh, M. L., Hunger, S. P., Borowitz, M., Wang, C., Guest, E., & Brown, P. A. (2023). Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631. Pediatric Blood and Cancer, 70(9), Article e30467. https://doi.org/10.1002/pbc.30467

@article{4cdb07fb39a24a208fa63a2704a2e22d,

title = "Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631",

abstract = "We measured minimal residual disease (MRD) by multiparameter flow cytometry at three time points (TP) in 117 infants with KMT2A (lysine [K]-specific methyltransferase 2A)-rearranged and 58 with KMT2A-germline acute lymphoblastic leukemia (ALL) on Children's Oncology Group AALL0631 study. For KMT2A-rearranged patients, 3-year event-free survival (EFS) by MRD-positive (≥0.01%) versus MRD-negative (<0.01%) was: TP1: 25% (±6%) versus 49% (±7%; p =.0009); TP2: 21% (±8%) versus 47% (±7%; p <.0001); and TP3: 22% (±14%) versus 51% (±6%; p =.0178). For KMT2A-germline patients, 3-year EFS was: TP1: 88% (±12%) versus 87% (±5%; p =.73); TP2: 100% versus 88% (±5%; p =.24); and TP3: 100% versus 87% (±5%; p =.53). MRD was a strong independent outcome predictor in KMT2A-rearranged, but not KMT2A-germline infant ALL.",

keywords = "acute lymphoblastic leukemia, infant leukemia, minimal residual disease",

author = "Faulk, {Kelly E.} and Kairalla, {John A.} and Dreyer, {Zo Ann E.} and Carroll, {Andrew J.} and Heerema, {Nyla A.} and Meenakshi Devidas and Carroll, {William L.} and Raetz, {Elizabeth A.} and Loh, {Mignon L.} and Hunger, {Stephen P.} and Michael Borowitz and Cindy Wang and Erin Guest and Brown, {Patrick A.}",

note = "Publisher Copyright: {\textcopyright} 2023 Wiley Periodicals LLC.",

year = "2023",

month = sep,

doi = "10.1002/pbc.30467",

language = "English",

volume = "70",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "9",

}

Faulk, KE, Kairalla, JA, Dreyer, ZAE, Carroll, AJ, Heerema, NA, Devidas, M, Carroll, WL, Raetz, EA, Loh, ML, Hunger, SP, Borowitz, M, Wang, C, Guest, E & Brown, PA 2023, 'Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631', Pediatric Blood and Cancer, vol. 70, no. 9, e30467. https://doi.org/10.1002/pbc.30467

Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631. / Faulk, Kelly E.; Kairalla, John A.; Dreyer, Zo Ann E. et al.
In: Pediatric Blood and Cancer, Vol. 70, No. 9, e30467, 09.2023.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia

T2 - Report from Children's Oncology Group study AALL0631

AU - Faulk, Kelly E.

AU - Kairalla, John A.

AU - Dreyer, Zo Ann E.

AU - Carroll, Andrew J.

AU - Heerema, Nyla A.

AU - Devidas, Meenakshi

AU - Carroll, William L.

AU - Raetz, Elizabeth A.

AU - Loh, Mignon L.

AU - Hunger, Stephen P.

AU - Borowitz, Michael

AU - Wang, Cindy

AU - Guest, Erin

AU - Brown, Patrick A.

PY - 2023/9

Y1 - 2023/9

N2 - We measured minimal residual disease (MRD) by multiparameter flow cytometry at three time points (TP) in 117 infants with KMT2A (lysine [K]-specific methyltransferase 2A)-rearranged and 58 with KMT2A-germline acute lymphoblastic leukemia (ALL) on Children's Oncology Group AALL0631 study. For KMT2A-rearranged patients, 3-year event-free survival (EFS) by MRD-positive (≥0.01%) versus MRD-negative (<0.01%) was: TP1: 25% (±6%) versus 49% (±7%; p =.0009); TP2: 21% (±8%) versus 47% (±7%; p <.0001); and TP3: 22% (±14%) versus 51% (±6%; p =.0178). For KMT2A-germline patients, 3-year EFS was: TP1: 88% (±12%) versus 87% (±5%; p =.73); TP2: 100% versus 88% (±5%; p =.24); and TP3: 100% versus 87% (±5%; p =.53). MRD was a strong independent outcome predictor in KMT2A-rearranged, but not KMT2A-germline infant ALL.

AB - We measured minimal residual disease (MRD) by multiparameter flow cytometry at three time points (TP) in 117 infants with KMT2A (lysine [K]-specific methyltransferase 2A)-rearranged and 58 with KMT2A-germline acute lymphoblastic leukemia (ALL) on Children's Oncology Group AALL0631 study. For KMT2A-rearranged patients, 3-year event-free survival (EFS) by MRD-positive (≥0.01%) versus MRD-negative (<0.01%) was: TP1: 25% (±6%) versus 49% (±7%; p =.0009); TP2: 21% (±8%) versus 47% (±7%; p <.0001); and TP3: 22% (±14%) versus 51% (±6%; p =.0178). For KMT2A-germline patients, 3-year EFS was: TP1: 88% (±12%) versus 87% (±5%; p =.73); TP2: 100% versus 88% (±5%; p =.24); and TP3: 100% versus 87% (±5%; p =.53). MRD was a strong independent outcome predictor in KMT2A-rearranged, but not KMT2A-germline infant ALL.

KW - acute lymphoblastic leukemia

KW - infant leukemia

KW - minimal residual disease

UR - http://www.scopus.com/inward/record.url?scp=85161429137&partnerID=8YFLogxK

U2 - 10.1002/pbc.30467

DO - 10.1002/pbc.30467

M3 - Article

C2 - 37259259

AN - SCOPUS:85161429137

SN - 1545-5009

VL - 70

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 9

M1 - e30467

ER -

Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631

Abstract

Keywords

Access to Document

Fingerprint

Cite this